Clinical trials: Dermatologic Diseases
Actinic Keratosis
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis
The purpose of this study is to compare safety and efficacy of Perrigo's drug compared to an FDA approved drug in the treatment of actinic keratosis.
- Trial name
- NCT02459795
- Testing
- Ingenol Mebutate (Perrigo), Ingenol Mebutate (Reference)
- Volunteers
- 469 people
- Sponsor
- Padagis LLC
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts…
- Trial name
- NCT06686394
- Testing
- Patritumab deruxtecan, Trastuzumab, Trastuzumab Biosimilar
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 181 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2-positive Breast Cancer
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
The purpose of the study is to identify molecular markers at the level of molecular pathway activation to predict efficacy of anti-HER2 therapy with Trastuzumab.
- Trial name
- NCT03521245
- Testing
- RNA sequencing, Transcriptome analysis, Trastuzumab
- Where
- 4 sites in United States, Russia
- Volunteers
- 40 people
- Sponsor
- OmicsWay Corp.
Eczema
A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
The study was designed to collect information over 1800 patients with a clinical diagnosis of subacute or chronic eczema, these patients' prescriptions contain Hirudoid®. EASI, IGA and more indicators are evaluated.
- Trial name
- NCT05439577
- Testing
- Mucopolysaccharide Polysulfate Cream, Mucopolysaccharide Polysulfate Cream and glucocorticoids
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis
- Trial name
- CADMUS Jr (NCT02698475)
- Testing
- Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Prostate Adenocarcinoma
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
The goal of this clinical research study is to evaluate the safety of PEG-BCT- 100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate…
- Trial name
- NCT02285101
- Testing
- PEG-BCT-100
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bio-Cancer Treatment International Limited
Warts
Topical 2% Povidone-Iodine Gel in Verruca Vulgaris
This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment.
- Trial name
- NCT04253912
- Testing
- VBP-245
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Veloce BioPharma LLC
Tinea Pedis
An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a…
- Trial name
- NCT01110330
- Testing
- Ketoconazole 2% cream (formulation F012) (Nizoral), Ketoconazole 2% cream (formulation F126)
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 583 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Breast Cancer, Tumors
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of bosutinib administered with multiple doses of ketoconazole and to provide the pharmacokinetic profile of bosutinib when…
- Conditions
- Breast Cancer, Tumors, Leukemia
- Trial name
- NCT00777530
- Testing
- Bosutinib (SKI-606)
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Skin Condition
Evaluation of Skin Attributes Following Dietary Supplement Consumption
The study is to assess skin attributes of female subjects following 16 weeks of dietary supplement consumption.
- Trial name
- NCT03487965
- Testing
- Low dose Polyphenol, High dose Polyphenol
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Access Business Group
Melanoma
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the…
- Trial name
- LOGIC-2 (NCT02159066)
- Testing
- LGX818, MEK162, LEE011
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Diabetic Foot Ulcer
Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.
The purpose of this study is to determine if AutoloGel platelet rich plasma used on non healing diabetic foot ulcers Wagner gd. 1 and 2 is more effective then the usual and customary care
- Trial name
- NCT01816672
- Testing
- AutoloGel, Usual and Customary Care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cytomedix
Melanoma, Metastases
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine.
- Trial name
- NCT00093119
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Celgene
Breast Cancer
A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.
Hypothesis: A higher sensitivity to breast cancer detection can be achieved in women with dense breast tissue by performing and reviewing results of Automated Breast Ultrasound (ABUS) and Digital X-Ray Mammography (XRM) together…
- Trial name
- somo•InSIGHT (NCT00816530)
- Testing
- Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
- Where
- 11 sites in United States
- Volunteers
- 15,679 people
- Sponsor
- U-Systems, Inc.
Small for Gestational Age (SGA) Infants, Appropriate for Gestational Age (AGA) Infants
An Observational Study to Characterize Human Milk From Mothers Delivering Term SGA and AGA Infants.
This is an observational study to characterize human milk of mothers delivering term SGA and term AGA infants. This is an observational, exploratory, longitudinal (from birth to 6 months postpartum), 4 parallel groups, and…
- Trial name
- NCT02421445
- Where
- 3 sites in India
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atopic Dermatitis, Eczema
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
There is a lack of prospective scientific data on the regular use of moisturizers in patients at risk of developing atopic dermatitis.
- Conditions
- Atopic Dermatitis, Eczema, Asthma, Food Allergies
- Trial name
- NCT01577628
- Testing
- Lipikar Balm AP
- Where
- 4 sites in United States, Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Malignant Neoplasm of Breast
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
This is A Phase III, randomized, two-armed, patient-outcome assessor-data analyzer blinded, parallel active controlled non-Inferiority clinical trial study to evaluate efficacy and safety of AryoTrust (Aryogen Trastuzumab in…
- Trial name
- NCT03425656
- Testing
- Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
- Where
- 19 sites in Iran
- Volunteers
- 108 people
- Sponsor
- AryoGen Pharmed Co.
Ovarian Cancer, Triple-negative Breast Cancer
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of rucaparib in combination with a second anticancer therapy in…
- Conditions
- Ovarian Cancer, Triple-negative Breast Cancer, Urothelial Carcinoma, Solid Tumor
- Trial name
- NCT03992131
- Testing
- Rucaparib, Lucitanib, Sacituzumab govitecan
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- pharmaand GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.